VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 456 filers reported holding VALEANT PHARMACEUTICALS INTL in Q1 2014. The put-call ratio across all filers is 0.78 and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $751,000 | -39.9% | 51,700 | +1.4% | 0.01% | -44.4% |
| Q3 2016 | $1,249,000 | +2.7% | 51,000 | -15.8% | 0.02% | 0.0% |
| Q2 2016 | $1,216,000 | -80.6% | 60,600 | -2.1% | 0.02% | -80.9% |
| Q4 2015 | $6,264,000 | -53.7% | 61,900 | -18.8% | 0.09% | -54.8% |
| Q3 2015 | $13,538,000 | -14.6% | 76,200 | +6.7% | 0.21% | -13.7% |
| Q2 2015 | $15,846,000 | +9.6% | 71,400 | -2.5% | 0.24% | +10.6% |
| Q1 2015 | $14,461,000 | +25.2% | 73,200 | -9.0% | 0.22% | +21.1% |
| Q4 2014 | $11,546,000 | +77.3% | 80,400 | +62.1% | 0.18% | +66.7% |
| Q3 2014 | $6,513,000 | +24.2% | 49,600 | +19.8% | 0.11% | +18.7% |
| Q2 2014 | $5,245,000 | -7.6% | 41,400 | -3.9% | 0.09% | -15.0% |
| Q1 2014 | $5,679,000 | +23.2% | 43,100 | +9.7% | 0.11% | +16.3% |
| Q4 2013 | $4,609,000 | +18.9% | 39,300 | +5.9% | 0.09% | +10.8% |
| Q3 2013 | $3,876,000 | +42.7% | 37,100 | +17.4% | 0.08% | +62.7% |
| Q2 2013 | $2,716,000 | – | 31,600 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Brave Warrior Advisors | 5,577,892 | $994,984,000 | 31.62% |
| Ruane, Cunniff & Goldfarb | 33,922,192 | $6,051,041,000 | 31.06% |
| LeVasseur Capital Partners LLC | 162,394 | $28,968,000 | 29.76% |
| FARLEY CAPITAL L.P. | 192,130 | $34,272,000 | 27.18% |
| Pershing Square Capital Management | 19,473,933 | $3,473,760,000 | 24.90% |
| Arrow Capital Management, LLC | 109,461 | $19,525,000 | 16.53% |
| Marble Arch Investments | 1,196,900 | $213,503,000 | 16.43% |
| Tesuji Partners | 1,368,040 | $244,414,000 | 15.82% |
| ValueAct Holdings | 14,994,261 | $2,674,676,000 | 15.55% |
| Hound Partners | 3,898,648 | $695,441,000 | 15.04% |